Therapy Area
Hepion shelves Phase II NASH trial amid shallow cash resources
The future of Hepion’s ASCEND-NASH study was already in the balance following cost-cutting measures last December.
The future of Hepion’s ASCEND-NASH study was already in the balance following cost-cutting measures last December.